FSD PHARMA Appoints Top GW Pharmaceuticals Executive, Rupert Haynes, As Chief Executive Officer
Channel: RICH TV LIVE
Date: 26/11/2018

FSD PHARMA Appoints Top GW Pharmaceuticals Executive, Rupert Haynes, As Chief Executive Officer - RICH TV LIVE - November 26, 2018 - FSD Pharma Inc. ("FSD Pharma" or "FSD") (CNSX:HUGE.CN) (OTCQB:FSDDF) (FRA: 0K9) announced today the appointment of Rupert Haynes as Chief Executive Officer. Mr. Haynes is a highly accomplished healthcare executive with nearly three decades of global pharmaceutical experience having most recently held the position of Head of Global Marketing at GW Pharmaceuticals (Nasdaq:GWPH) in the United Kingdom. In his new role with FSD Pharma, Mr. Haynes will continue to work out of the United Kingdom, which will support FSD Pharma's strategy of expanding its global footprint. Interim CEO and Co-chairman of the board, Dr. Raza Bokhari will remain in place as CEO until Mr. Haynes officially assumes the role.

"Mr. Haynes has an impressive track record in pipeline and product development which is directly relevant to FSD's vision of becoming a global cannabinoid based pharmaceutical leader," said Dr. Raza Bokhari, Co-chairman of the Board. "He blends world class specialty pharmaceutical experience with a fast-paced biotech mindset that will help accelerate FSD's growth and global expansion strategy by assembling a top tier management team and pursuing targeted mergers & acquisitions. On behalf of the Board, I welcome him to the company."

As head of Global Marketing at GW Pharmaceuticals, Mr. Haynes oversaw the strategic development of the firm's cannabinoid portfolio including numerous cannabinoid pipeline products across dozens of therapeutic areas, but primarily neurological, neurodegenerative and neuropsychological conditions. Mr. Haynes was also involved in the strategic planning & development of Epidiolex(R), an FDA-approved cannabidiol, for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome. Before GW, Mr. Haynes held numerous commercial roles, including senior leadership positions, at both large pharma and bespoke biotech firms which include Sobi, UCB Pharma, Bristol-Myers Squibb Ltd, UK, and Pharmacia & Upjohn Ltd, UK.

"This is an exciting time to be joining FSD," said Mr. Rupert Haynes, CEO of FSD Pharma. "The company is advancing at a rapid pace having recently announced a pilot study for SCN-001 in irritable bowel syndrome through its collaboration with SciCann and intention to acquire Therapix Biosciences where there are active clinical trials evaluating cannabinoid combination therapies. I look forward to continuing this fast-paced pharmaceutical development which could lead to multiple significant new development programs in a very short timeframe."

Subscribe - https://www.youtube.com/c/RICHTVLIVE
Visit - http://www.richtvlive.com/ a one-stop shop for cryptocurrency, stocks, sports, travel and trending topics. #richtvlive #breakingnews #money  
Join the RICH TV LIVE FREE Social Media Community - Download the Amino app on your phone or computer and follow the link - https://aminoapps.com/c/RICHTVLIVE/home/
Join the Conversation get the RICH TV LIVE app at Google Play - https://play.google.com/store/apps/details?id=com.app.richtvlive
iPhone App Store - https://itunes.apple.com/us/app/richtvlive/id1212158240?Is=1&mt=8

Popular Uploads - https://goo.gl/tbvXGg
Most Recent Upload - https://goo.gl/unKXBy
YouTube Channel Page - https://goo.gl/yUdG7w
Subscribe - https://goo.gl/q2tLnn
Rich TV Live Playlist - https://goo.gl/e116JF
YouTube support Tubebuddy - https://www.tubebuddy.com/RICHTVLIVE

Disclaimer

Rich TV's company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in Rich TV reports company profiles or other investor relations materials and presentations are subject to change. Rich TV and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.

Investing is inherently risky. Rich TV is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.

We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov.